Table 2.

Reported prevalence rates of MOG-IgG seropositivity (based on cell-based assays) among patients with neuromyelitis optica spectrum disorder (NMOSD) and limited/related forms, according to phenotype and aquaporin-4 immunoglobulin G (AQP4-IgG) status.

Reference	Sample description	Prevalence of MOG-IgG seropositivity
		Irrespective of AQP4-IgG status	Among AQP4-IgG seronegative	Among AQP4-IgG seropositive
Mader et al. (9)	Definite neuromyelitis optica (NMO)	3/45 (6.7%)	2/2 (100%)	1/45 (2.2%)
	High-risk NMO [longitudinally extensive transverse myelitis (LETM) or recurrent ON]	7/53 (13.2%)	7/21 (33.3%)	0/32 (0%)
Kitley et al. (8)	NMO/NMOSD	4/71 (5.6%)	4/27 (14.8%)	0/44 (0%)
Rostasy et al. (52)	Children with recurrent ON	12/15 (80%)	12/15 (80%)	0/0 (0%)
Rostásy et al. (53)	Children with definite NMO	3/8 (37.5%)	3/6 (50%)	0/2 (0%)
Höftberger et al. (50)	Definite NMO	6/48 (12.5%)	4/9 (44.4%)	2/39 (5.1%)
	LETM	5/84 (6%)	5/68 (7.4%)	0/16 (0%)
	Severe, bilateral, or recurrent ON	7/39 (17.9%)	7/33 (21,2%)	0/6 (0%)
Ramanathan et al. (54)	AQP4-IgG-seronegative NMO/NMOSD	N/A	9/23 (39.1%)	N/A
Sato et al. (48)	Definite NMO	1/101 (1%)	1/16 (6.2%)	0/85 (0%)
	LETM	5/78 (6.4%)	5/35 (14.3%)	0/43 (0%)
	Bilateral or recurrent ON	10/36 (27.8%)	10/25 (40%)	0/11 (0%)
Chalmoukou et al. (55)	AQP4-seronegative ON (uni- or bilateral, monophasic, or recurrent)	N/A	8/111 (7.2%)	N/A
Cobo-Calvo et al. (56)	AQP4-IgG-seronegative LETM	N/A	13/56 (23.2%)	N/A
Hyun et al. (57)	Isolated LETM	4/108 (3.7%)	4/53 (7.5%)	0/55 (0%)
Kim et al. (58)	Definite NMO	0/23 (0%)	0/3 (0%)	0/20 (0%)
	Recurrent or bilateral ON	10/30 (33.3%)	10/25 (40%)	0/5 (0%)
Pröbstel et al. (59)	NMO/NMOSD	4/48 (8.3%)	4/17 (23.5%)	0/31 (0%)
Siritho et al. (60)	AQP4-seronegative idiopathic inflammatory central nervous system diseases with a non-multiple sclerosis phenotype	N/A	6/29 (20.7%)	N/A
Yan et al. (61)	NMOSD	24/125 (19.2%)	14/46 (30.4%)	10/79 (12.7%)
van Pelt et al. (51)	NMOSD or limited forms	N/A	20/61 (32.8%)	N/A

N/A, not available.